PICALM and Alzheimer's Disease: An Update and Perspectives

被引:34
|
作者
Ando, Kunie [1 ]
Nagaraj, Siranjeevi [1 ]
Kucukali, Fahri [2 ]
De Fisenne, Marie-Ange [1 ]
Kosa, Andreea-Claudia [1 ]
Doeraene, Emilie [1 ]
Gutierrez, Lidia Lopez [1 ]
Brion, Jean-Pierre [1 ]
Leroy, Karelle [1 ]
机构
[1] Univ Libre Bruxelles, Fac Med, ULB Neurosci Inst, Lab Histol Neuropathol & Neuroanat, 808 Route Lenn, B-1070 Brussels, Belgium
[2] Univ Antwerp, VIB Ctr Mol Neurol, Dept Biomed Sci, VIB Antwerp,Complex Genet Alzheimers Dis Grp, B-2000 Antwerp, Belgium
关键词
PICALM; Alzheimer's disease; GWAS; amyloid beta; neurofibrillary tangles; microglia; CLATHRIN ASSEMBLY PROTEIN; GENOME-WIDE ASSOCIATION; ACTIVATED NEUTRAL PROTEINASE; AMYLOID-BETA; NEUROFIBRILLARY TANGLES; A-BETA; MEDIATED ENDOCYTOSIS; POSTTRANSLATIONAL MODIFICATIONS; IDENTIFIES VARIANTS; REDUCES A-BETA-42;
D O I
10.3390/cells11243994
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Genome-wide association studies (GWAS) have identified the PICALM (Phosphatidylinositol binding clathrin-assembly protein) gene as the most significant genetic susceptibility locus after APOE and BIN1. PICALM is a clathrin-adaptor protein that plays a critical role in clathrin-mediated endocytosis and autophagy. Since the effects of genetic variants of PICALM as AD-susceptibility loci have been confirmed by independent genetic studies in several distinct cohorts, there has been a number of in vitro and in vivo studies attempting to elucidate the underlying mechanism by which PICALM modulates AD risk. While differential modulation of APP processing and A beta transcytosis by PICALM has been reported, significant effects of PICALM modulation of tau pathology progression have also been evidenced in Alzheimer's disease models. In this review, we summarize the current knowledge about PICALM, its physiological functions, genetic variants, post-translational modifications and relevance to AD pathogenesis.
引用
收藏
页数:26
相关论文
共 50 条
  • [41] Clinical update on Alzheimer's disease immunotherapies
    Grundman, Michael
    NEUROBIOLOGY OF AGING, 2008, 29 : S11 - S11
  • [42] Alzheimer's Disease: An Update and Insights Into Pathophysiology
    Abubakar, Murtala Bello
    Sanusi, Kamaldeen Olalekan
    Ugusman, Azizah
    Mohamed, Wael
    Kamal, Haziq
    Ibrahim, Nurul Husna
    Khoo, Ching Soong
    Kumar, Jaya
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
  • [43] Targeting Metals in Alzheimer's Disease: An Update
    Du, Bin
    Chen, Kang
    Wang, Weiwei
    Lei, Peng
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 101 : S141 - S154
  • [44] Ropinirole in the treatment of Alzheimer's disease: An update
    Vivancos-Matellano, K.
    REVISTA DE NEUROLOGIA, 2006, 42 (09) : 542 - 548
  • [45] Pharmacologic treatment of Alzheimer's disease: An update
    Delagarza, VW
    AMERICAN FAMILY PHYSICIAN, 2003, 68 (07) : 1365 - 1372
  • [46] Vascular factors in Alzheimer's disease: An update
    Kalaria, Raj N.
    SOUTH AFRICAN JOURNAL OF PSYCHIATRY, 2012, 18 (03) : 109 - 109
  • [47] Rivastigmine in the treatment of Alzheimer's disease: an update
    Onor, Maria Luisa
    Trevisiol, Marianna
    Aguglia, Eugenio
    CLINICAL INTERVENTIONS IN AGING, 2007, 2 (01): : 17 - 32
  • [48] Aducanumab in Alzheimer's Disease: A Critical Update
    Ashique, Sumel
    Sirohi, Ekta
    Kumar, Shubneesh
    Rihan, Mohd
    Mishra, Neeraj
    Bhatt, Shvetank
    Gautam, Rupesh K.
    Singh, Sachin Kumar
    Gupta, Gaurav
    Chellappan, Dinesh Kumar
    Dua, Kamal
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (31) : 5004 - 5026
  • [49] Update on the Pharmacological Treatment of Alzheimer's Disease
    Massoud, Fadi
    Gauthier, Serge
    CURRENT NEUROPHARMACOLOGY, 2010, 8 (01) : 69 - 80
  • [50] Pharmacological Approaches of Alzheimer's Disease: An Update
    Khan, Safia A.
    Krishna, Kamsagara L.
    Parikh, Ajay J.
    Priya
    Dodi, Sudha R.
    CURRENT DRUG THERAPY, 2011, 6 (03) : 186 - 196